TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A November 6 MedPage Today opinion article says Democrats’ gains in the November 3, 2026, midterms could give them leverage to pursue healthcare priorities, including reversing Medicaid cuts and restoring Affordable Care Act premium subsidies. Those goals are not enacted policy: funding, presidential vetoes, Senate procedures and the new Congress’s strategy remain major hurdles.
Democrats’ gains in the November 3 midterm elections may give them an opening to challenge the Trump administration on healthcare, but they will face funding and legislative obstacles, according to a November 6 opinion article by Steven Grossman in MedPage Today. Grossman identifies reversing Medicaid cuts and restoring Affordable Care Act premium subsidies as potential priorities, while stressing that neither outcome is assured.
Grossman argues that healthcare was among the issues contributing to voter dissatisfaction and that Democrats will need to produce concrete results during the next two years. That is his analysis of the election, not a finding that voters supported a particular healthcare plan. The source provides no election results by state, chamber margins or voter survey details that would establish the scale of Democrats’ governing power.
The immediate legislative window is the lame-duck session between the election and the new Congress’s scheduled start on January 3, 2027. Grossman expects little healthcare legislation to pass during that period, reasoning that measures without broad bipartisan backing face time limits and procedural hurdles. He anticipates that the session will focus chiefly on appropriations and defense matters.
Once the new Congress convenes, Democrats could investigate administration policy, pass bills that President Donald Trump could veto, attach provisions to must-pass legislation, or seek compromises, Grossman writes. He points to the next FDA user-fee reauthorization as a possible vehicle for other measures, including the Clinical Trial Modernization Act. The reauthorization must become law by September 30, 2027, and Grossman says lawmakers would ideally complete it by June or July.
The Cost of Democrats’ Health Goals
The proposed priorities carry direct consequences for people who rely on Medicaid or buy insurance through the Affordable Care Act marketplaces. Reversing Medicaid cuts could affect program funding and coverage; restoring premium subsidies could change the cost of marketplace plans. However, Grossman’s article does not specify the provisions, eligibility rules or number of people affected, so the practical effects cannot yet be quantified.
Grossman says financing is a central constraint: Democrats would need to identify $1.2 trillion over 10 years to pay for the ambitions described. He presents creating a reconciliation bill as the easier step and finding that funding as the harder one. Reconciliation can allow certain budget legislation to pass the Senate with 51 votes, but it does not remove the need to meet procedural rules or secure support among lawmakers.
The political stakes extend beyond the policy details. If Democrats cannot turn campaign-era concerns into legislation, Grossman warns, voters could hold them responsible. That is a forecast in an opinion article, not a confirmed prediction of future voter behavior.
Products Worth Considering
Fitbit Sense 2 Health and Fitness Smartwatch, Shadow Grey/Graphite
Withings BPM Vision Blood Pressure Monitor with Wi-Fi and Bluetooth
Therabody Theragun Relief Massage Gun, 3-Speed, Black
As an affiliate, we earn on qualifying purchases.
The Post-Election Legislative Calendar
The article was published three days after the midterm vote. The incoming Congress is scheduled to begin January 3, 2027; until then, the current Congress remains in office for a lame-duck period. Grossman says this short interval is unlikely to produce major healthcare legislation unless a proposal has bipartisan support and lawmakers make it a priority.
Grossman also discusses Health and Human Services Secretary Robert F. Kennedy Jr. and a proposed FDA leadership appointment. He predicts Kennedy could face hostile investigations by Democratic-led health committees and speculates that Kennedy may resign. He also argues that a controversial FDA commissioner nominee would have little chance of confirmation during the lame-duck session and could fare worse with a Democratic-led Senate. These are the author’s expectations; the source does not report a resignation, a confirmation vote or an announced change to the nomination.
“Democrats must deliver.”
— Steven Grossman, JD, in MedPage Today
Policy Plans Still Taking Shape
The source does not establish the final composition or margins of the incoming Congress, nor does it identify a settled Democratic strategy. Grossman says it is too early to know whether lawmakers will emphasize investigations, standalone bills, legislative riders or compromise. The article also does not detail the proposed Medicaid changes or subsidy restoration, or explain how the $1.2 trillion estimate was calculated.
It remains unclear whether Kennedy will stay in office, whether the administration will put forward a different FDA commissioner nominee, and whether any proposed legislation will gain enough support to pass. Trump’s response to specific measures, including whether he would veto them, will depend on legislation that has not yet been introduced or negotiated.
Votes and Deadlines in 2027
The next formal milestone is the new Congress’s scheduled opening on January 3, 2027. Lawmakers will then set committee priorities and decide whether to hold hearings on administration health policies. Any nomination that expires when the new Congress begins would need to be submitted again if the White House still wishes to pursue it.
Later in 2027, attention is likely to turn to the FDA user-fee reauthorization, which must become law by September 30. Grossman expects lawmakers may seek to attach other health measures, but neither that approach nor the inclusion of the Clinical Trial Modernization Act has been confirmed. The timing, bill text, financing plan and prospects for bipartisan agreement remain to be determined.
Key Questions
What healthcare priorities does the article identify?
Grossman identifies undoing Medicaid program cuts and restoring Affordable Care Act premium subsidies as priorities Democrats could pursue. The article does not provide final legislative proposals.
Have Democrats passed these healthcare changes?
No. The article discusses possible actions after the midterms; it does not report that either policy has been enacted.
Why is the funding question important?
Grossman says the agenda would require finding $1.2 trillion over 10 years. The article does not explain the estimate’s calculation or identify an agreed funding source.
When does the new Congress begin?
The article gives January 3, 2027 as the scheduled start date. The current Congress remains in office during the intervening lame-duck session.
Will Robert F. Kennedy Jr. leave his post?
That is not confirmed. Grossman predicts Kennedy could resign amid congressional scrutiny, but the article reports no resignation announcement.
Source: medpagetoday.com
